NASD · Healthcare · Health Information Services · USA
Certara Inc is a small cap company (market value between $300 million and $2 billion) in the Health Information Services industry.
Certara provides biosimulation technology and advisory services to the biopharmaceutical and biotech industries. The company offers mechanistic and empirical modeling solutions, along with regulatory science platforms, enabling life sciences companies to optimize drug development programs. Its software products are used by thousands of researchers across pharmaceutical firms, academic institutions, and global drug regulatory agencies.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Certara Inc stock.
Overvalued: intrinsic value $8.37 per share, market price $11.06, margin of safety -32.1% (as of 2026-11-17).
Discounting its cash flows at 10.0% (average of 2 methods) values the shares at $8.37; the price of $11.06 is 32% above that value, and 73% of that value comes from beyond year five.
17 more funds hold it; the full list is part of the paid plan.
All 40 Health Information Services stocks
3 more in this industry show a wider margin of safety.
CERT is overvalued (as of the 2026-11-17 close). Discounting its cash flows at 10.0% (average of 2 methods) values the shares at $8.37; the price of $11.06 is 32% above that value, and 73% of that value comes from beyond year five.
$8.37 per share (as of the 2026-11-17 close), against a market price of $11.06. That is a margin of safety of -32.1%. The value is the average of the 2 valuation methods that apply to this company, recomputed every night after the US close.